Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) EBIT: 2009-2024

Historic EBIT for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Dec 2024 value amounting to $195.1 million.

  • Catalyst Pharmaceuticals' EBIT rose 30.17% to $66.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $258.8 million, marking a year-over-year increase of 48.74%. This contributed to the annual value of $195.1 million for FY2024, which is 124.77% up from last year.
  • As of FY2024, Catalyst Pharmaceuticals' EBIT stood at $195.1 million, which was up 124.77% from $86.8 million recorded in FY2023.
  • Catalyst Pharmaceuticals' 5-year EBIT high stood at $195.1 million for FY2024, and its period low was $41.3 million during FY2020.
  • Its 3-year average for EBIT is $127.9 million, with a median of $101.8 million in 2022.
  • Its EBIT has fluctuated over the past 5 years, first fell by 14.75% in 2023, then spiked by 124.77% in 2024.
  • Over the past 5 years, Catalyst Pharmaceuticals' EBIT (Yearly) stood at $41.3 million in 2020, then increased by 26.83% to $52.4 million in 2021, then soared by 94.40% to $101.8 million in 2022, then dropped by 14.75% to $86.8 million in 2023, then spiked by 124.77% to $195.1 million in 2024.